Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
Aim. An overview of current pharmacotherapy for non-alcoholic steatohepatitis (NASH)-associated liver fibrosis.Key points. In current clinical recommendations, therapeutic measures in non-alcoholic fatty liver disease should include lifestyle change, body weight normalisation, NASH-associated liver...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2022-01-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/646 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860076761317376 |
|---|---|
| author | D. V. Garbuzenko |
| author_facet | D. V. Garbuzenko |
| author_sort | D. V. Garbuzenko |
| collection | DOAJ |
| description | Aim. An overview of current pharmacotherapy for non-alcoholic steatohepatitis (NASH)-associated liver fibrosis.Key points. In current clinical recommendations, therapeutic measures in non-alcoholic fatty liver disease should include lifestyle change, body weight normalisation, NASH-associated liver fibrosis-specific drug therapy and treatment for metabolic syndrome-related diseases. Given a lack of approved antifibrotic therapies in NASH, several drugs have nevertheless demonstrated an adequate efficacy and safety in phase 3 clinical trials, also in compensated cirrhosis, which allows their practical validation in phase 4.Conclusion. The understanding of liver fibrosis as an adverse natural consequence of non-alcoholic fatty liver disease clearly attests for an early introduction and wide use of antifibrotic therapy to improve NASH outcomes and avoid associated complications. |
| format | Article |
| id | doaj-art-c40ccb5963614b7c839a10276044543b |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2022-01-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-c40ccb5963614b7c839a10276044543b2025-02-10T16:14:37ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732022-01-01315162410.22416/1382-4376-2021-31-5-16-24444Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver FibrosisD. V. Garbuzenko0South Ural State Medical UniversityAim. An overview of current pharmacotherapy for non-alcoholic steatohepatitis (NASH)-associated liver fibrosis.Key points. In current clinical recommendations, therapeutic measures in non-alcoholic fatty liver disease should include lifestyle change, body weight normalisation, NASH-associated liver fibrosis-specific drug therapy and treatment for metabolic syndrome-related diseases. Given a lack of approved antifibrotic therapies in NASH, several drugs have nevertheless demonstrated an adequate efficacy and safety in phase 3 clinical trials, also in compensated cirrhosis, which allows their practical validation in phase 4.Conclusion. The understanding of liver fibrosis as an adverse natural consequence of non-alcoholic fatty liver disease clearly attests for an early introduction and wide use of antifibrotic therapy to improve NASH outcomes and avoid associated complications.https://www.gastro-j.ru/jour/article/view/646non-alcoholic steatohepatitisliver fibrosisdrug therapy |
| spellingShingle | D. V. Garbuzenko Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis Российский журнал гастроэнтерологии, гепатологии, колопроктологии non-alcoholic steatohepatitis liver fibrosis drug therapy |
| title | Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis |
| title_full | Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis |
| title_fullStr | Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis |
| title_full_unstemmed | Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis |
| title_short | Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis |
| title_sort | drug therapy for non alcoholic steatohepatitis induced liver fibrosis |
| topic | non-alcoholic steatohepatitis liver fibrosis drug therapy |
| url | https://www.gastro-j.ru/jour/article/view/646 |
| work_keys_str_mv | AT dvgarbuzenko drugtherapyfornonalcoholicsteatohepatitisinducedliverfibrosis |